| Funding Opportunity ID: |
333063 |
| Opportunity Number: |
PAR-21-233 |
| Opportunity Title: |
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) |
| Opportunity Category: |
Discretionary |
| Opportunity Category Explanation: |
|
| Funding Instrument Type: |
Cooperative Agreement |
| Category of Funding Activity: |
Education
Health
Income Security and Social Services |
| Category Explanation: |
|
| CFDA Number(s): |
93.121
93.213
93.242
93.273
93.279
93.286
93.853
93.865
93.866
93.867 |
| Eligible Applicants: |
Small businesses |
| Additional Information on Eligibility: |
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
| Agency Code: |
HHS-NIH11 |
| Agency Name: |
Department of Health and Human Services
National Institutes of Health |
| Posted Date: |
Apr 23, 2021 |
| Close Date: |
Apr 05, 2024 |
| Last Updated Date: |
Apr 23, 2021 |
| Award Ceiling: |
$0 |
| Award Floor: |
$0 |
| Estimated Total Program Funding: |
|
| Expected Number of Awards: |
|
| Description: |
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program. |
| Version: |
1 |
|
